| scholarly article | Q13442814 |
| P50 | author | Eui Hyun Kim | Q88007302 |
| P2093 | author name string | Ju-Seog Lee | |
| Kee Hwan Kwon | |||
| Young Chan Lee | |||
| Bo Hwa Sohn | |||
| Dongjin Lee | |||
| Sun Young Yim | |||
| Young-Gyu Eun | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
| A comparison of normalization methods for high density oligonucleotide array data based on variance and bias | Q27860710 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 | ||
| The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP | Q28266862 | ||
| Mutational landscape and significance across 12 major cancer types | Q28300353 | ||
| The mutational landscape of head and neck squamous cell carcinoma | Q29614654 | ||
| Multiclass cancer diagnosis using tumor gene expression signatures | Q29615780 | ||
| The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis | Q29619851 | ||
| hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts | Q29620457 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Q30275266 | ||
| The Hippo signaling pathway in stem cell biology and cancer | Q30410176 | ||
| Analysis of gene expression data using BRB-ArrayTools. | Q33448521 | ||
| Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer | Q33849646 | ||
| KRAS and YAP1 converge to regulate EMT and tumor survival | Q33946244 | ||
| Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis | Q34077954 | ||
| Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene | Q34267908 | ||
| Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. | Q34602664 | ||
| Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder | Q34840601 | ||
| Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer | Q34946875 | ||
| Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival | Q35085742 | ||
| Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis | Q35742770 | ||
| A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma | Q35752244 | ||
| Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients | Q35885488 | ||
| The emerging roles of YAP and TAZ in cancer | Q36035567 | ||
| A 13-gene signature prognostic of HPV-negative OSCC: discovery and external validation | Q36672862 | ||
| Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma | Q36939981 | ||
| The Hippo pathway and human cancer. | Q38087215 | ||
| Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma | Q38828541 | ||
| PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. | Q38838649 | ||
| Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial | Q38849759 | ||
| The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma | Q38890549 | ||
| The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer | Q38903548 | ||
| YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer | Q38978179 | ||
| Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | Q38996832 | ||
| Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. | Q39586964 | ||
| The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. | Q40814745 | ||
| Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway | Q44591663 | ||
| Application of comparative functional genomics to identify best-fit mouse models to study human cancer | Q45163567 | ||
| miRWalk2.0: a comprehensive atlas of microRNA-target interactions | Q46692723 | ||
| Shar-pei mediates cell proliferation arrest during imaginal disc growth in Drosophila | Q47072038 | ||
| Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. | Q48364922 | ||
| A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells | Q50115050 | ||
| Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. | Q52087746 | ||
| The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. | Q52100108 | ||
| Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. | Q53386271 | ||
| Head and neck cancer | Q54152939 | ||
| Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment. | Q54356882 | ||
| Head and neck cancer | Q70522684 | ||
| P433 | issue | 67 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 111130-111143 | |
| P577 | publication date | 2017-11-27 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Clinical significance of YAP1 activation in head and neck squamous cell carcinoma | |
| P478 | volume | 8 |
| Q92821373 | Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations |
| Q92715223 | Expression of glucose transporter-1, hypoxia inducible factor-1α and beclin-1 in head and neck cancer and their implication |
| Q91808467 | Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck |
| Q96576943 | Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine |
| Q98784904 | The potential role of YAP in head and neck squamous cell carcinoma |
| Q92627373 | Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1 |
| Q90613256 | YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma |
| Q91591189 | [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis] |
| Q92590225 | miR-506 is a YAP1-dependent tumor suppressor in laryngeal squamous cell carcinoma |
Search more.